GlaxoSmithKline to buy Boston Pharmaceuticals unit for up to $2 billion

May 19, 2025 Source: drugdu 81

GlaxoSmithKline and Boston Pharmaceuticals announced on May 14 that they have reached an agreement for GlaxoSmithKline to acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, to obtain the sales rights of Efimosfermin, a Phase III clinical-ready, investigational specialty drug for the treatment of fatty liver disease (SLD). Under the agreement, GlaxoSmithKline will pay an upfront payment of $1.2 billion and may pay additional milestone payments totaling up to $800 million.